Andrographolide inhibits CYP3A4 activity by binding and antagonizing PXR function, and is a potential CYP3A4 inhibitor that may have clinical significance (Ooi et al., 2011)
Clinical trial data from the NEJM Phase 2 study showed that gastrointestinal events were predominantly mild to moderate, occurred primarily during dose escalation, and were partially mitigated by starting at 2mg rather than 4mg
[DOI] [PubMed] [Google Scholar] 22.Falone S., Mirabilio A., Pennelli A., Cacchio M., Di Baldassarre A., Gallina S., Passerini A., Amicarelli F
This IV is especially effective as most COVID-19 patients have high levels of inactive glutathione, and results can be seen in as little as ten minutes after administering lipoic acid
C.LamanJ
What research areas involve BPC-157